Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 30, Issue 2, pp 192–199 | Cite as

Advanced age, low left atrial appendage velocity, and Factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation

  • Dmitry A. Zateyshchikov
  • Alexey N. Brovkin
  • Dimitry A. ChistiakovEmail author
  • Valery V. Nosikov
Article

Abstract

Atrial fibrillation (AF) renders individual patients at risk for development of an atrial thrombus. The aim of this study was to determine clinical and echocardiographic factors influencing the risk of left atrial thrombosis (LAT) in patients with persistent nonvalvular AF. Genetic variants encoding haemostatic factors have been also assessed for putative association with LAT. In the cross-sectional study, a total of 212 patients (132 males and 80 females) with nonvalvular persistent AF (duration range 48 h-90 days) have been selected. LAT was visualized by transesophageal echocardiography. The FGB G(-455)A, PAI-1 4G/5G, F5 C(-224)T, and F5 R506Q genetic markers were tested using the polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) approach. To reveal independent factors contributing to the thromboembolic risk in AF, a multivariate logistic model was applied. LA thrombi were found in 44 out of 212 subjects (21%). LAT was more frequently observed in patients at age >75 years (P < 0.001) and those who had reduced left ventricular ejection fraction <40% (LVEF; P < 0.001) and decreased left atrial appendage velocity <20 cm/s (LAAV; P < 0.001). Logistic regression analysis showed that advanced age (OR = 1.64 per decade P < 0.001), LVEF < 40% (OR = 2.12, P < 0.001), LAAV (OR = 1.56, P = 0.007), and TT genotype of F5 C(-224)T (OR = 2.42, P = 0.041) are associated with higher risk of LAT. Age >75 years, LVEF < 40%, LAAV < 20 cm/s, and Factor V C(-224)T variant independently contribute to the thromboembolic risk in AF.

Keywords

Atrial fibrillation Atrial thrombosis Left atrial appendage velocity Factor V Polymorphism Association 

Notes

Acknowledgments

This work was funded by the grant 07-04-01032-a from the Russian Foundation for Basic Research.

References

  1. 1.
    Khasnis A, Thakur RK (2009) Atrial fibrillation: a historical perspective. Cardiol Clin 27:1–12CrossRefPubMedGoogle Scholar
  2. 2.
    Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 147:1561–1564CrossRefPubMedGoogle Scholar
  3. 3.
    Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82:2N–9NCrossRefPubMedGoogle Scholar
  4. 4.
    Leung DY, Davidson PM, Cranney GB, Walsh WF (1997) Thromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram. Am J Cardiol 79:626–629CrossRefPubMedGoogle Scholar
  5. 5.
    Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 373:155–166CrossRefPubMedGoogle Scholar
  6. 6.
    Heppell RM, Berkin KE, McLenachan JM, Davies JA (1997) Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 77:407–411PubMedGoogle Scholar
  7. 7.
    Topsuoglu MA, Haydari D, Otzurk S, Ozcebe OI, Sabias O (2000) Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation. Neurol Sci 21:235–240CrossRefGoogle Scholar
  8. 8.
    Sakurai K, Hirai T, Nakagawa K, Kameyaga T, Nozawa T, Asanoi H, Inoue H (2003) Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter. Chest 124:1670–1674CrossRefPubMedGoogle Scholar
  9. 9.
    Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY (2007) Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 132:1253–1258CrossRefPubMedGoogle Scholar
  10. 10.
    Akar JG, Jeske W, Wilber DJ (2008) Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 51:1790–1793CrossRefPubMedGoogle Scholar
  11. 11.
    Dougu N, Takashima S, Sasahara E, Taguchi Y, Toyoda S, Hirai T, Nozawa T, Tanaka K, Inoue H (2008) Differential diagnosis of cerebral infarction using an algorithm combining atrial fibrillation and D-dimer level. Eur J Neurol 15:295–300CrossRefPubMedGoogle Scholar
  12. 12.
    Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, Shimizu A, Hayano M, Yano K (2008) Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. Int J Cardiol 126:316–321CrossRefPubMedGoogle Scholar
  13. 13.
    Pretorius M, Donahue BS, Yu C, Greelish JP, Roden DM, Brown NJ (2007) Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 116(Suppl):I1–I7CrossRefPubMedGoogle Scholar
  14. 14.
    Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H (2008) Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation. Thromb Res 121:447–453CrossRefPubMedGoogle Scholar
  15. 15.
    Marin F, Roldan V, Lip GY (2003) Fibrinolytic function and atrial fibrillation. Thromb Res 109:233–240CrossRefPubMedGoogle Scholar
  16. 16.
    Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC Jr, Harrison DG, Langberg JJ (2002) Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106:2854–2858CrossRefPubMedGoogle Scholar
  17. 17.
    Tsantes AE, Nikopouloos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G (2008) The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 122:736–742CrossRefPubMedGoogle Scholar
  18. 18.
    Tsantes AE, Nikolopoulos GK, Bagos PG, Tsiara C, Kapsimali V, Travlou A, Vaiopoulos G (2007) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis 18:497–504CrossRefPubMedGoogle Scholar
  19. 19.
    Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V, Travlou A (2007) Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis: a meta-analysis. Thromb Haemost 97:907–913PubMedGoogle Scholar
  20. 20.
    Duga S, Asselta R, Tenchini ML (2005) Coagulation factor V. Int J Biochem Cell Biol 36:1393–1399CrossRefGoogle Scholar
  21. 21.
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67CrossRefPubMedGoogle Scholar
  22. 22.
    Nicolaes GAF, Dahlback B (2002) Factor V and thrombotic disease. Arterioscler Thromb Vasc Biol 22:530–538CrossRefPubMedGoogle Scholar
  23. 23.
    Van’t Hooft FM, von Bahr SJ, Silveira A, Iliadou A, Eriksson P, Hamsten A (1999) Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Artherioscler Thromb Vasc Biol 19:3063–3070Google Scholar
  24. 24.
    Reiner AP, Carty CL, Carlson CS et al (2006) Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the coronary artery risk development in young adults (CARDIA) study. J Thromb Haemost 4:1279–1287CrossRefPubMedGoogle Scholar
  25. 25.
    Siegerink B, Rosendaal FR, Algra A (2009) Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost 7:385–390CrossRefPubMedGoogle Scholar
  26. 26.
    de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AV, Kluft C (1998) 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. Arterioscler Thromb Vasc Biol 18:265–271PubMedGoogle Scholar
  27. 27.
    Kessler C, Spitzer C, Stauske D, Mende S, Stadlmuller J, Walther R, Rettig R (1997) The apolipoproten E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 17:2880–2884PubMedGoogle Scholar
  28. 28.
    Martiskainen M, Pohjasvaara T, Mikkelsson J, Mantyla R, Kunnas T, Laippala P, Ilvekoski E, Kaste M, Karhunen PJ, Erkinjuntti T (2003) Fibrinogen risk promoter -544 A allele as a risk factor for lacunar stroke. Stroke 34:886–891CrossRefPubMedGoogle Scholar
  29. 29.
    Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo T, Ikeda U, Shimada K, Matsuo M (1998) Genetic variation in the promoter region of the beta-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 9:373–379CrossRefPubMedGoogle Scholar
  30. 30.
    Xu X, Li J, Sheng W, Liu L (2008) Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis 26:48–62CrossRefPubMedGoogle Scholar
  31. 31.
    Pongracz E, Andrikovics H, Csornai M, Bernat IS, Nagy Z (2006) Contribution of the -455G/A polymorphism at beta-fibrinogen gene and of the Leiden mutation to hemorheological parameters in ischemic stroke patients. Clin Hemorheol Microcirc 35:75–82PubMedGoogle Scholar
  32. 32.
    Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL et al (2001) ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American society of pacing and electrophysiology. Eur Heart J 22:1852–1923CrossRefPubMedGoogle Scholar
  33. 33.
    Otto CM (2002) The practice of clinical echocardiography, 2nd edn. WB Saunders Co, Philadelphia, PAGoogle Scholar
  34. 34.
    The CriteriaCommittee of the New York Heart Association (1994) Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9th edn. Little, Brown & Co, Boston, MA, pp 253–256Google Scholar
  35. 35.
    Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d’Addedda M, Di Minno G (1997) An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 77:605–606PubMedGoogle Scholar
  36. 36.
    Klein RL, Hunter SJ, Jenkins AJ, Zheng D, Semler AJ, Clore J, Garvey GT (2003) Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 26:1439–1448CrossRefPubMedGoogle Scholar
  37. 37.
    Della Valle CJ, Issack PS, Baitner A, Stejger DJ, Fang C, Di Cesare PE (2001) The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskelet Disord 2:1CrossRefPubMedGoogle Scholar
  38. 38.
    Moulton AW, Singer DE, Haas JS (1991) Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med 91:156–161CrossRefPubMedGoogle Scholar
  39. 39.
    Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457CrossRefGoogle Scholar
  40. 40.
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 285:2864–2870CrossRefPubMedGoogle Scholar
  41. 41.
    Stroke Risk in Atrial Fibrillation Working Group (2007) Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69:546–554CrossRefGoogle Scholar
  42. 42.
    Hylek EM, Go AS, Chang YC, Jensvold NG, Henault LE, Selby JV, Singer DE (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Eng J Med 349:1019–1026CrossRefGoogle Scholar
  43. 43.
    Pozzoli M, Febo O, Torbicki A, Tramarin R, Calsamiglia G, Cobelli F, Specchia G, Roelandt JR (1991) Left atrial appendage dysfunction: a cause of thrombosis? Evidence by transesophageal echocardiography-Doppler studies. J Am Soc Echocardiogr 4:435–441PubMedGoogle Scholar
  44. 44.
    ELAT study (Embolism in Left Atrial Thrombi) (1995) Baseline clinical and echocardiographic data. Cardiology 86:457–463CrossRefGoogle Scholar
  45. 45.
    Rader VJ, Khumri TM, Idupalati M, Stoner CN, Magalski A, Main ML (2007) Clinical predictors of left atrial thrombus and spontaneous echocardiographic contrast in patients with atrial fibrillation. J Am Soc Echocardiogr 20:1181–1185CrossRefPubMedGoogle Scholar
  46. 46.
    Handke M, Harloff A, Hetzel A, Olschewski M, Bode C, Geibel A (2005) Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation—a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr 18:1366–1372CrossRefPubMedGoogle Scholar
  47. 47.
    Fatkin D, Kelly RP, Feneley MP (1994) Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 23:961–969CrossRefPubMedGoogle Scholar
  48. 48.
    Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R (1999) Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The stroke prevention in atrial fibrillation [SPAF-III] study. J Am Soc Echocardiogr 12:1080–1087CrossRefPubMedGoogle Scholar
  49. 49.
    SPAF III Investigators (1998) Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The stroke prevention in atrial fibrilation investigators committee on echocardiography. Ann Intern Med 128:639–647Google Scholar
  50. 50.
    Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, Bovill EG (1999) Markers of thrombin, platelet activity in patients with atrial fibrillation. Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 30:2547–2553PubMedGoogle Scholar
  51. 51.
    Go AS, Reed GL, Hylek EM, Philips KA, Liu L, Henault LE, Selby JV, Singer DE (2003) Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Thromb Thrombolysis 15:41–46CrossRefPubMedGoogle Scholar
  52. 52.
    Pengo V, Filippi B, Biasiolo A, Pegoraro C, Naventa F, Iliceto S (2002) Association of the G20210A mutation in the Factor II gene with systemic embolism in nonvalvular atrial fibrillation. Am J Cardiol 90:545–546CrossRefPubMedGoogle Scholar
  53. 53.
    Poli D, Antonucci E, Cecchi E et al (2003) Thrombophilic mutations in high-risk atrial fibrillation patients: high prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism. Thromb Haemost 90:1158–1162PubMedGoogle Scholar
  54. 54.
    Berge E, Haug KB, Sandset EC, Haugbro KK, Turkovic M, Sandset PM (2007) The factor V Leiden, prothrombin gene 20210GA, methylenetetrahydrofolate reductase 677CT and platelet glycoprotein IIIa 1565TC mutations in patients with acute ischemic stroke and atrial fibrillation. Stroke 38:1069–1071CrossRefPubMedGoogle Scholar
  55. 55.
    Hatzinikolaou-Kotsakou E, Kartasis Z, Tziakas D, Hotidis A, Stakos D, Tsalatas K, Bourikas G, Kotsakou ME, Hatseras DI (2003) Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations? J Thromb Thrombolysis 16:155–161CrossRefPubMedGoogle Scholar
  56. 56.
    Eriksson JG, Forsen T, Tuomilehto J, Osmond C, Barker DJP (2000) Early growth, adult income, and risk of stroke. Original contributions. Stroke 31:869–874PubMedGoogle Scholar
  57. 57.
    Marin F, Roldan V, Tello A, Lip GY (2004) Genetic polymorphisms and thromboembolic risk in atrial fibrillation. J Thromb Thrombolysis 18:151–152CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Dmitry A. Zateyshchikov
    • 1
  • Alexey N. Brovkin
    • 2
  • Dimitry A. Chistiakov
    • 2
    Email author
  • Valery V. Nosikov
    • 1
  1. 1.Scientific-Educational Medical Center of the Department of General Management of Russian PresidentMoscowRussia
  2. 2.Department of Molecular DiagnosticsNational Research Center GosNIIgenetikaMoscowRussia

Personalised recommendations